Coverage you can inspect
Coverage and sources: what is available and what is missing?
A link or successful automated check does not establish complete country coverage or review of every document. This page separates available content, monitoring evidence and gaps.
Scientific coverage across 11 fields
| Field | Available now | Next step |
|---|---|---|
| Manufacturing and quality | 6 new working guides | Open field resources |
| Drug development | 2 new working guides | Open field resources |
| Practice and medicine information | 1 new working guides | Open field resources |
| Registration and regulation | 1 new working guides | Open field resources |
| Vigilance and safety | 1 new working guides | Open field resources |
| Supply and distribution | 1 new working guides | Open field resources |
| Research and publishing | 1 new working guides | Open field resources |
| Devices and diagnostics | 1 new working guides | Open field resources |
| Economics and access | 1 new working guides | Open field resources |
| Data and informatics | 1 new working guides | Open field resources |
| Professional learning | Existing student and learning pathways | Open field resources |
Guide counts do not measure specialist depth. Reviewing every existing calculator, study and legacy case, and documenting human reviewers, remains separate work that is not claimed complete.
Open the official authority directory for all 22 Arab countries — Documented authority gateways are available; automated monitoring is separately stated below.
Monitoring evidence for all 22 Arab countries
This uses the site’s existing monitoring-status service; opening the page does not start collection or publication. Additional discovery requires editorial review before publication.
Reading operational evidence…
| Country | Mapped source | Monitoring mode | Latest available result | Latest attempt · Dubai time |
|---|---|---|---|---|
| Algeria | Authority and official links ANPP | Additional notice discovery | Reading check status… | — |
| Bahrain | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Comoros | Authority and official links ANAMEV | Additional notice discovery | Reading check status… | — |
| Djibouti | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Egypt | Authority and official links EDA | Core monitoring | Reading check status… | — |
| Iraq | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Jordan | Authority and official links JFDA | Core monitoring | Reading check status… | — |
| Kuwait | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Lebanon | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Libya | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Mauritania | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Morocco | Authority and official links AMMPS | Additional notice discovery | Reading check status… | — |
| Oman | Authority and official links OMAN_DSC | Additional notice discovery | Reading check status… | — |
| Palestine | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Qatar | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Saudi Arabia | Authority and official links SFDA | Core monitoring | Reading check status… | — |
| Somalia | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Sudan | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Syria | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
| Tunisia | Authority and official links ANMPS | Additional notice discovery | Reading check status… | — |
| United Arab Emirates | Authority and official links EDE | Additional notice discovery | Reading check status… | — |
| Yemen | Authority and official links | No documented mapping in this statement | Monitoring evidence gap | — |
Source register for the new guides
Source pages and cited points were checked on 3 October 2026. Document status and effective date are distinct from that check date.
| Primary source | Scope | Version and status |
|---|---|---|
| EU GMP · Chapter 1 | European Union · pharmaceutical quality system | Chapter 1, revision 3; operational since 31 January 2013 |
| ICH Q9(R1) · EMA | Quality risk management; check local adoption | EU effective from 26 July 2023; corrected-version page |
| EU GMP · Annex 1 | European Union · sterile manufacture | 2022 revision; fully applicable from 25 August 2024 |
| EU GMP · Annex 15 | European Union · qualification and validation | 2015 revision; operational from 1 October 2015 |
| EMA · Health-based exposure limits | Exposure limits in shared facilities | Adopted guidance; current first version published in 2014 |
| FDA · Process Validation | United States · process validation lifecycle | Final guidance, January 2011 |
| FDA · OOS investigations | United States · out-of-specification laboratory results | Revision 1, May 2022; guidance recommendations are nonbinding |
| ICH Q2(R2) · EMA | Validation of analytical procedures | EU effective from 14 June 2024 |
| ICH Q14 · EMA | Analytical procedure development and maintenance | EU effective from 14 June 2024; page updated 24 February 2026 |
| ICH Q1A(R2) · EMA | Stability of new drug substances and products within the guideline scope | Current effective version; EU effective 1 August 2003 |
| ICH Q1 · consolidated stability draft | Proposed consolidated stability guidance | Step 2b draft; consultation closed, not final on the EMA page checked |
| FDA · Data integrity Q&A | United States · CGMP data integrity | Final guidance, December 2018 |
| ICH M13A · EMA | BE for immediate-release oral solid dosage forms delivering drug systemically | EU effective from 25 January 2025 |
| ICH · Common Technical Document | Dossier organisation; Module 1 is region-specific | CTD structure page; submission requirements depend on the authority |
| EMA · Good pharmacovigilance practices | European Union · pharmacovigilance | Final-module index; Module III revision 2 effective from 10 September 2026 |
| NLM · DailyMed: scope and limitations | United States · submitted, in-use labelling | Living database description; each label has its own date |
| EU · GDP guidelines 2013/C 343/01 | European Union · distribution of human medicines | Published 23 November 2013; listed in EudraLex |
| IMDRF · Essential Principles N47 | International convergence principles; do not replace market requirements | N47 FINAL:2024, edition 2; 26 April 2024 |
| ClinicalTrials.gov | Submitted study records and results | Living registry; inspect each study’s update date |
| EQUATOR Network | Research reporting quality and transparency | Research reporting guideline network |
| EMA · Biosimilar medicines overview | European Union · biosimilar medicines | Living overview; consult the relevant product guideline too |
| European Commission · HTA | European Union · health technology assessment | HTA portal and implementation documents |
| European Commission · EudraLex Volume 4 | European GMP and GDP | Version and applicability index; checked 3 October 2026 |
What still needs completion?
- Assign and document specialist human review for high-impact material.
- Expand geographical monitoring with verified sources and ingestion checks, documenting each source’s limits.
- Assess the existing calculators and scientific cases individually.
- Run usability studies with pharmacists and students and performance measurements on real phones.